|
|
|
|
ShcA Protects against Epithelial–Mesenchymal Transition through Compartmentalized Inhibition of TGF-β-Induced Smad Activation
|
|
|
|
|
|
|
|
نویسنده
|
muthusamy b.p. ,budi e.h. ,katsuno y. ,lee m.k. ,smith s.m. ,mirza a.m. ,akhurst r.j. ,derynck r.
|
|
منبع
|
plos biology - 2015 - دوره : 13 - شماره : 12
|
|
چکیده
|
Epithelial–mesenchymal transition (emt) is a normal cell differentiation event during development and contributes pathologically to carcinoma and fibrosis progression. emt often associates with increased transforming growth factor-β (tgf-β) signaling,and tgf-β drives emt,in part through smad-mediated reprogramming of gene expression. tgf-β also activates the erk mapk pathway through recruitment and tyr phosphorylation of the adaptor protein shca by the activated tgf-β type i receptor. we found that shca protects the epithelial integrity of nontransformed cells against emt by repressing tgf-β-induced,smad-mediated gene expression. p52shca competed with smad3 for tgf-β receptor binding,and down-regulation of shca expression enhanced autocrine tgf-β/smad signaling and target gene expression,whereas increased p52shca expression resulted in decreased smad3 binding to the tgf-β receptor,decreased smad3 activation,and increased erk mapk and akt signaling. furthermore,p52shca sequestered tgf-β receptor complexes to caveolin-associated membrane compartments,and reducing shca expression enhanced the receptor localization in clathrin-associated membrane compartments that enable smad activation. consequently,silencing shca expression induced emt,with increased cell migration,invasion,and dissemination,and increased stem cell generation and mammosphere formation,dependent upon autocrine tgf-β signaling. these findings position shca as a determinant of the epithelial phenotype by repressing tgf-β-induced smad activation through differential partitioning of receptor complexes at the cell surface. © 2015 muthusamy et al.
|
|
|
|
|
آدرس
|
departments of cell and tissue biology,university of california,san francisco,ca,united states,eli and edythe broad center of regeneration medicine and stem cell research,university of california,san francisco,ca, United States, departments of cell and tissue biology,university of california,san francisco,ca,united states,eli and edythe broad center of regeneration medicine and stem cell research,university of california,san francisco,ca, United States, departments of cell and tissue biology,university of california,san francisco,ca,united states,eli and edythe broad center of regeneration medicine and stem cell research,university of california,san francisco,ca,united states,department of molecular pathology,graduate school of medicine,the university of tokyo,bunkyo-ku,tokyo,113-0033, Japan, center for craniofacial molecular biology,ostrow school of dentistry,university of southern california,los angeles,ca, United States, center for craniofacial molecular biology,ostrow school of dentistry,university of southern california,los angeles,ca, United States, xoma corp.,berkeley,ca, United States, eli and edythe broad center of regeneration medicine and stem cell research,university of california,san francisco,ca,united states,department of anatomy,university of california,san francisco,ca,united states,helen diller comprehensive cancer center,university of california,san francisco,ca, United States, departments of cell and tissue biology,university of california,san francisco,ca,united states,eli and edythe broad center of regeneration medicine and stem cell research,university of california,san francisco,ca,united states,department of anatomy,university of california,san francisco,ca,united states,helen diller comprehensive cancer center,university of california,san francisco,ca, United States
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|